Notable Analyst Rating Changes 12/4: (TEVA) (HBI) (HPP) Upgraded; (M)( GPRO) (KSU) Downgraded
Guggenheim upgrades Teva Pharma (NYSE: TEVA) from Neutral to Buy with a price target of $80. Click Here ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)